Mozavaptan

Chemical compound

none

Legal statusLegal status

In general: ℞ (Prescription only)

Identifiers

IUPAC name

N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide

CAS Number

137975-06-5^Y

PubChem CID

119369

IUPHAR/BPS

2197

ChemSpider

106618^Y

UNII

17OJ42922Y

ChEMBL

ChEMBL420762^Y

CompTox Dashboard (EPA)

DTXSID8057641

Chemical and physical dataFormulaC₂₇H₂₉N₃O₂Molar mass427.548 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C

InChI

InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)^Y
Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N^Y

^NY (what is this?) (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
"Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006. Archived from the original on 2012-02-13.

Diuretics (C03)

Sulfonamides
(and etacrynic acid)

CA inhibitors (at PT)	Acetazolamide
Loop (Na-K-Cl at AL)	Furosemide^# Azosemide Bumetanide Etacrynic acid Etozolin Indacrinone Muzolimine Ozolinone Piretanide Tienilic acid^‡ Torasemide
Thiazides (Na-Cl at DCT, Calcium-sparing)	Altizide Bendroflumethiazide Butizide Chlorothiazide Cyclopenthiazide Cyclothiazide Epitizide Hydrochlorothiazide Hydroflumethiazide Mebutizide Methyclothiazide Polythiazide Trichlormethiazide
Thiazide-likes (primarily DCT)	Chlortalidone Clofenamide Clopamide Clorexolone Fenquizone Indapamide Mefruside Meticrane Metolazone Quinethazone Xipamide

Potassium-sparing (at CD)

ESC blockers	Amiloride^# Benzamil Triamterene
Aldosterone antagonists	Spirolactones Spironolactone^# Canrenone Eplerenone Potassium canrenoate Nonsteroidal Finerenone

Osmotic diuretics (PT, DL)

Vasopressin receptor inhibitors
(DCT and CD)

Vaptans
- Conivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan

Others
- Demeclocycline
- Lithium carbonate

Other

Ethanol, Isopropanol, 2M2B
mercurial diuretics (Chlormerodrin, Mersalyl, Meralluride)
Theobromine
Cicletanine

Combination products

Hydrochlorothiazide/triamterene

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Oxytocin and vasopressin receptor modulators

Oxytocin

Agonists: Peptide: Aspartocin
Carbetocin
Cargutocin
Demoxytocin
Lipo-oxytocin-1
Merotocin
Nacartocin
Oxytocin
PF-06478939
PF-06655075 (PF1)
TGOT
Vasotocin (argiprestocin); Non-peptide: CA7
LIT-001
TC OT 39
WAY-267464
WJ0679

Antagonists: Peptide: Atosiban
Tocinoic acid; Non-peptide: Barusiban
Cligosiban
Epelsiban
Erlosiban
IX-01
L-368,899
L-371,257
L-372,662
Nolasiban
Retosiban
SSR-126768
WAY-162720

Vasopressin

V_1A	Agonists: Felypressin Lypressin Ornipressin Selepressin Terlipressin Vasopressin (argipressin) Vasotocin (argiprestocin) Antagonists: Atosiban Balovaptan Conivaptan FR-218944 JNJ-17079166 JNJ-17308616 LIT-001 LY-307174 PF-184563 Relcovaptan SRX246 SRX251 TC OT 39 WAY-267464 YM-218 YM-471 YM-35471
V_1B	Agonists: Desmopressin Felypressin Lypressin Ornipressin Terlipressin Vasopressin (argipressin) Vasotocin (argiprestocin) Antagonists: ABT-436 ABT-558 Nelivaptan ORG-52186 (SCH-740935) TASP-0233278 TASP-0390325 TS-121 Ligands: TASP-699
V₂	Agonists: Desmopressin Felypressin LIT-001 Lypressin Ornipressin TC OT 39 Terlipressin Vasopressin (argipressin) Vasotocin (argiprestocin) Antagonists: Conivaptan JNJ-17079166 Lixivaptan Mozavaptan RWJ-351647 Satavaptan Tolvaptan YM-471 YM-35471
Unsorted	Antagonists: Balovaptan Ribuvaptan RWJ-339489 VMAX-367 VMAX-372 VMAX-382 YM-222546 Other inhibitors: Demeclocycline Lithium (lithium carbonate)